Welcome to our dedicated page for Pro-Dex Colo SEC filings (Ticker: PDEX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Looking for the story behind Pro-Dex’s precision surgical drivers and motion-control boards? Most investors start by scanning a single Form 8-K, then realise the real details hide across hundreds of pages of 10-K, 10-Q and proxy statements. This page brings every Pro-Dex SEC filing into one place and, more importantly, explains what each document means for revenue tied to a handful of medical-device OEMs, FDA compliance costs, and new driver technology in development.
Use Stock Titan’s AI summaries to turn the dense language of a Pro-Dex annual report 10-K simplified into clear bullet points, or let our engine flag sudden shifts in backlog within the latest Pro-Dex quarterly earnings report 10-Q filing. Need immediate alerts? We stream Pro-Dex Form 4 insider transactions real-time so you can track director purchases the moment they hit EDGAR. Curious about pay packages? The Pro-Dex proxy statement executive compensation section is distilled so you can compare cash bonuses to patent milestones in seconds.
Common tasks become effortless: monitor Pro-Dex insider trading Form 4 transactions before material announcements, dissect segment margins with our Pro-Dex earnings report filing analysis, and see every Pro-Dex 8-K material events explained without opening a single PDF. Whether you’re underwriting credit, valuing the stock, or simply understanding Pro-Dex SEC documents with AI, this hub delivers all filings, real-time updates, and plain-English insights—so you spend time on decisions, not document mining.
Pro-Dex, Inc. furnished a Form 8-K announcing it is issuing a press release covering financial performance for its first fiscal quarter ended September 30, 2025. The Item 2.02 information is expressly furnished, not filed for purposes of Section 18 of the Exchange Act. The press release is included as Exhibit 99.1.
Pro-Dex, Inc. reported stronger quarterly results. Net sales were $18.53 million, up 24% year over year, as orthopedic product shipments recovered and CMF drivers grew. Gross margin was 29% versus 35% a year ago, reflecting higher product costs, under‑absorption, and lower repair margins.
Operating income was $3.11 million. Other income rose to $3.11 million, including $3.30 million of unrealized gains on investments. Net income was $4.68 million, with diluted EPS of $1.40. Cash was $0.51 million and investments measured at fair value totaled $10.19 million. Working capital was $37.12 million. Notes payable were $13.28 million, and $2.16 million was drawn on the revolving loan.
Backlog was approximately $46.8 million, with $43.6 million scheduled for delivery during the remainder of fiscal 2026. Customer concentration remained high: one customer represented 78% of revenue and 84% of gross receivables. After quarter‑end, Pro-Dex received $8.9 million in cash from the Monogram sale and expects to record a $6.8 million realized gain in the next quarter; it also received contingent value rights tied to future milestones.
Pro‑Dex, Inc. discloses ownership, governance, compensation and equity-plan details in its definitive proxy. There are 3,280,004 shares outstanding and a group of directors, named executives and related parties hold 1,505,896 shares (45.9%). AO Partners I, L.P. holds 922,204 shares and those shares are pledged as collateral for a bank loan.
Board biographies highlight long tenure and industry experience in finance and medical devices. Executive pay descriptions show base salaries (CEO base noted at
Pro-Dex, Inc. filed its Form 10-K for fiscal 2025 describing operations in medical and scientific devices, including segment sales, balance sheet highlights, financing activity, and governance disclosures. Repairs revenue rose to $18,586 (up from $16,505), CMF sales totaled $9,943 (down ~4%), and thoracic sales increased by $1.3 million to $4.3 million. Operating income improved to $10,689 from $7,173. Investments carried net unrealized gains of $3.3 million at June 30, 2025 versus $1.8 million a year earlier. The company purchased a property for $6.5 million financed with a $5.2 million Property Loan. The revolving credit line was increased to $11.0 million and term loans carry maturities through 2029–2030 with a $3.1 million balloon due at maturity. Share repurchases totaled 130,148 shares at $3.5 million in fiscal 2025. The filing discloses customer concentration (major customer represented ~75% of sales) and notes cybersecurity risk management and standard risk-factor disclosures.
FAQ
What is the current stock price of Pro-Dex Colo (PDEX)?
What is the market cap of Pro-Dex Colo (PDEX)?
